SUITO Index for Evaluation of Clinical Islet Transplantation

The major endpoints for clinical islet transplantation for type 1 diabetes are insulin independence and reduction of hypoglycemic episodes. Both endpoints are influenced by patients' and physicians' preferences regarding the use of exogenous insulin. Therefore, development of an objective...

Full description

Bibliographic Details
Main Authors: Morihito Takita M.D., Ph.D., Shinichi Matusmoto
Format: Article
Language:English
Published: SAGE Publishing 2012-07-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368912X636885
_version_ 1830452731152695296
author Morihito Takita M.D., Ph.D.
Shinichi Matusmoto
author_facet Morihito Takita M.D., Ph.D.
Shinichi Matusmoto
author_sort Morihito Takita M.D., Ph.D.
collection DOAJ
description The major endpoints for clinical islet transplantation for type 1 diabetes are insulin independence and reduction of hypoglycemic episodes. Both endpoints are influenced by patients' and physicians' preferences regarding the use of exogenous insulin. Therefore, development of an objective endpoint for assessing clinical islet transplantation is desirable. HOMA-beta score is useful in assessing functional β-cell mass. However, this score uses blood insulin levels that are influenced by exogenous insulin injection and therefore is not suitable for patients who receive exogenous insulin. For assessing functional β-cell mass for type 1 diabetic patients after islet transplantation, we created the Secretory Unit of Islet Transplant Objects (SUITO) index using fasting C-peptide and fasting glucose. The formula of the SUITO index is fasting C-peptide (ng/ml)/[fasting blood glucose – 63 (mg/dl)] x 1500. We demonstrated that, within 1 month of islet transplantation, an average SUITO index of >26 was an excellent predictor of achieving insulin independence. In addition, daily SUITO index scores correlated with a reduction of insulin dose and adversely correlated with blood glucose levels during an intravenous glucose tolerance test. Other important endpoints, reduction of hypoglycemic episodes and quality of life, also correlated with the SUITO index. Thus, the SUITO index is excellent for assessing important endpoints (insulin independence, reduction of hypoglycemia, improved quality of life) after allogeneic islet transplantation.
first_indexed 2024-12-21T08:54:34Z
format Article
id doaj.art-832e2989f64c4ad385759e0373bb7951
institution Directory Open Access Journal
issn 0963-6897
1555-3892
language English
last_indexed 2024-12-21T08:54:34Z
publishDate 2012-07-01
publisher SAGE Publishing
record_format Article
series Cell Transplantation
spelling doaj.art-832e2989f64c4ad385759e0373bb79512022-12-21T19:09:36ZengSAGE PublishingCell Transplantation0963-68971555-38922012-07-012110.3727/096368912X636885SUITO Index for Evaluation of Clinical Islet TransplantationMorihito Takita M.D., Ph.D.0Shinichi Matusmoto1 The Institute of Medical Science, University of Tokyo, Tokyo, Japan The Institute of Medical Science, University of Tokyo, Tokyo, JapanThe major endpoints for clinical islet transplantation for type 1 diabetes are insulin independence and reduction of hypoglycemic episodes. Both endpoints are influenced by patients' and physicians' preferences regarding the use of exogenous insulin. Therefore, development of an objective endpoint for assessing clinical islet transplantation is desirable. HOMA-beta score is useful in assessing functional β-cell mass. However, this score uses blood insulin levels that are influenced by exogenous insulin injection and therefore is not suitable for patients who receive exogenous insulin. For assessing functional β-cell mass for type 1 diabetic patients after islet transplantation, we created the Secretory Unit of Islet Transplant Objects (SUITO) index using fasting C-peptide and fasting glucose. The formula of the SUITO index is fasting C-peptide (ng/ml)/[fasting blood glucose – 63 (mg/dl)] x 1500. We demonstrated that, within 1 month of islet transplantation, an average SUITO index of >26 was an excellent predictor of achieving insulin independence. In addition, daily SUITO index scores correlated with a reduction of insulin dose and adversely correlated with blood glucose levels during an intravenous glucose tolerance test. Other important endpoints, reduction of hypoglycemic episodes and quality of life, also correlated with the SUITO index. Thus, the SUITO index is excellent for assessing important endpoints (insulin independence, reduction of hypoglycemia, improved quality of life) after allogeneic islet transplantation.https://doi.org/10.3727/096368912X636885
spellingShingle Morihito Takita M.D., Ph.D.
Shinichi Matusmoto
SUITO Index for Evaluation of Clinical Islet Transplantation
Cell Transplantation
title SUITO Index for Evaluation of Clinical Islet Transplantation
title_full SUITO Index for Evaluation of Clinical Islet Transplantation
title_fullStr SUITO Index for Evaluation of Clinical Islet Transplantation
title_full_unstemmed SUITO Index for Evaluation of Clinical Islet Transplantation
title_short SUITO Index for Evaluation of Clinical Islet Transplantation
title_sort suito index for evaluation of clinical islet transplantation
url https://doi.org/10.3727/096368912X636885
work_keys_str_mv AT morihitotakitamdphd suitoindexforevaluationofclinicalislettransplantation
AT shinichimatusmoto suitoindexforevaluationofclinicalislettransplantation